Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Robert McQueen

Concepts (270)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cost-Benefit Analysis
31
2026
632
3.560
Why?
Drug Costs
7
2025
115
2.130
Why?
Negotiating
4
2025
34
1.840
Why?
Quality-Adjusted Life Years
12
2024
119
1.670
Why?
Diabetes Mellitus, Type 1
11
2026
3930
1.500
Why?
Medicare
4
2025
907
1.350
Why?
Models, Economic
8
2025
63
1.270
Why?
Blood Glucose Self-Monitoring
5
2026
704
1.220
Why?
Patient-Centered Care
3
2025
551
1.160
Why?
Antibodies, Monoclonal, Humanized
8
2026
992
1.150
Why?
Health Services Needs and Demand
2
2026
283
1.030
Why?
Health Expenditures
3
2024
196
0.980
Why?
Genetic Therapy
3
2025
303
0.940
Why?
Multiple Sclerosis, Relapsing-Remitting
3
2015
66
0.920
Why?
Natalizumab
4
2015
30
0.920
Why?
Drug Industry
1
2025
46
0.890
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
2
2022
448
0.890
Why?
Financing, Government
1
2025
53
0.890
Why?
Research Support as Topic
1
2025
81
0.880
Why?
Technology Assessment, Biomedical
3
2022
44
0.870
Why?
National Institutes of Health (U.S.)
1
2025
147
0.860
Why?
Reimbursement Mechanisms
1
2025
78
0.830
Why?
Immunologic Factors
3
2015
244
0.820
Why?
Asthma
6
2023
1800
0.800
Why?
United States
21
2026
16041
0.800
Why?
Decision Support Techniques
4
2022
473
0.800
Why?
Ovarian Neoplasms
2
2020
598
0.790
Why?
Medicaid
2
2025
472
0.780
Why?
Diabetic Retinopathy
1
2026
211
0.780
Why?
Hemophilia B
1
2023
65
0.760
Why?
Antineoplastic Agents, Immunological
1
2025
200
0.740
Why?
Azetidines
1
2022
45
0.740
Why?
Endometriosis
1
2023
58
0.720
Why?
Hypercholesterolemia
1
2022
95
0.690
Why?
Hemophilia A
1
2023
149
0.680
Why?
Diabetes Mellitus, Type 2
3
2024
2623
0.660
Why?
Anticholesteremic Agents
1
2022
156
0.650
Why?
Anemia, Sickle Cell
1
2025
322
0.640
Why?
Humans
66
2026
145625
0.620
Why?
Value-Based Purchasing
1
2019
8
0.610
Why?
Carcinoma, Non-Small-Cell Lung
2
2026
1194
0.590
Why?
Academies and Institutes
1
2019
60
0.590
Why?
Poly(ADP-ribose) Polymerase Inhibitors
1
2020
137
0.560
Why?
Patient Outcome Assessment
1
2019
128
0.560
Why?
Atherosclerosis
1
2022
410
0.560
Why?
Hypoglycemic Agents
3
2024
1411
0.550
Why?
Health Care Costs
2
2020
418
0.550
Why?
Biological Therapy
1
2018
28
0.550
Why?
Blood Glucose
5
2026
2357
0.530
Why?
Foodborne Diseases
3
2024
60
0.520
Why?
Telephone
1
2018
175
0.500
Why?
Mass Screening
3
2026
1300
0.500
Why?
Health Priorities
2
2026
45
0.460
Why?
Health Benefit Plans, Employee
1
2015
24
0.460
Why?
Lung Neoplasms
2
2026
2674
0.440
Why?
Research Design
4
2024
1139
0.420
Why?
Stakeholder Participation
2
2026
90
0.410
Why?
Anti-Asthmatic Agents
4
2018
263
0.400
Why?
Insulin
1
2024
2524
0.380
Why?
Hypoglycemia
2
2024
489
0.380
Why?
Cardiovascular Diseases
2
2022
2218
0.380
Why?
Female
29
2026
79080
0.370
Why?
Markov Chains
4
2025
128
0.370
Why?
Drug Monitoring
1
2015
399
0.350
Why?
Metformin
1
2015
328
0.350
Why?
Immunotherapy, Adoptive
3
2019
356
0.330
Why?
Insurance Claim Review
2
2024
85
0.320
Why?
Cost of Illness
4
2024
322
0.320
Why?
Male
25
2026
73014
0.320
Why?
Medication Adherence
1
2015
535
0.320
Why?
Severity of Illness Index
3
2017
2910
0.310
Why?
Costs and Cost Analysis
3
2020
216
0.310
Why?
Decision Making
5
2026
987
0.310
Why?
Renal Insufficiency, Chronic
1
2017
639
0.310
Why?
Middle Aged
20
2026
36359
0.290
Why?
Adult
19
2026
40821
0.270
Why?
Parkinson Disease
2
2026
614
0.270
Why?
Aged
13
2026
26251
0.270
Why?
Adolescent
13
2026
22451
0.270
Why?
Diabetes Mellitus
1
2017
1101
0.270
Why?
Young Adult
12
2026
14240
0.270
Why?
Neoplasms
2
2020
2944
0.260
Why?
Autoantibodies
3
2026
1498
0.250
Why?
Retrospective Studies
11
2026
17291
0.240
Why?
Drug Therapy, Combination
4
2022
1034
0.240
Why?
Comparative Effectiveness Research
2
2025
170
0.230
Why?
Colorado
4
2025
4588
0.230
Why?
Public-Private Sector Partnerships
1
2025
44
0.220
Why?
Multimorbidity
1
2025
65
0.220
Why?
Health Policy
2
2026
399
0.210
Why?
Omalizumab
2
2023
44
0.210
Why?
Syphilis
1
2024
39
0.210
Why?
Heterocyclic Compounds, 2-Ring
1
2023
18
0.190
Why?
Thiadiazoles
1
2023
25
0.190
Why?
Hydrocarbons, Fluorinated
1
2023
8
0.190
Why?
Dicarboxylic Acids
1
2022
12
0.190
Why?
Ezetimibe
1
2022
24
0.190
Why?
Pregnancy in Diabetics
1
2024
123
0.190
Why?
Insurance Coverage
1
2024
246
0.180
Why?
Follow-Up Studies
2
2026
5397
0.170
Why?
Diabetic Ketoacidosis
2
2026
212
0.170
Why?
Glomerular Filtration Rate
2
2017
743
0.170
Why?
Incidence
2
2026
2910
0.170
Why?
Food Microbiology
1
2021
39
0.170
Why?
Insurance, Health
1
2024
315
0.170
Why?
Pharmaceutical Preparations
1
2022
172
0.160
Why?
Cholesterol, LDL
1
2022
363
0.160
Why?
Models, Econometric
2
2018
35
0.160
Why?
Randomized Controlled Trials as Topic
3
2020
1754
0.160
Why?
Treatment Outcome
9
2022
11744
0.160
Why?
Eicosapentaenoic Acid
1
2020
37
0.160
Why?
Palliative Care
2
2026
1032
0.160
Why?
Aged, 80 and over
5
2026
8351
0.150
Why?
Fees, Medical
1
2019
9
0.150
Why?
Patient Participation
1
2024
454
0.150
Why?
Perception
1
2022
372
0.150
Why?
Longitudinal Studies
2
2024
3005
0.150
Why?
Hospitalization
5
2026
2468
0.150
Why?
Teicoplanin
1
2019
15
0.150
Why?
Fatty Acids
1
2022
460
0.150
Why?
Patient Acceptance of Health Care
1
2026
880
0.140
Why?
Pyrimidines
1
2023
530
0.140
Why?
Early Diagnosis
1
2020
249
0.140
Why?
Indazoles
1
2019
86
0.140
Why?
Phthalazines
1
2019
63
0.140
Why?
Computer Simulation
2
2026
1014
0.140
Why?
Gram-Positive Bacterial Infections
1
2019
72
0.140
Why?
Case-Control Studies
1
2026
3633
0.140
Why?
Disease Progression
1
2026
2857
0.130
Why?
England
1
2018
106
0.130
Why?
Open Access Publishing
1
2017
6
0.130
Why?
Antigens, CD19
1
2019
137
0.130
Why?
Rivaroxaban
1
2020
270
0.130
Why?
Piperidines
1
2019
223
0.130
Why?
Peer Review, Research
1
2017
36
0.130
Why?
Caregivers
1
2026
1079
0.130
Why?
Dry Powder Inhalers
1
2017
1
0.130
Why?
Data Collection
1
2020
647
0.130
Why?
Heparin
1
2019
246
0.130
Why?
Lymphoma, B-Cell
1
2019
149
0.130
Why?
Metered Dose Inhalers
1
2017
8
0.130
Why?
Time Factors
2
2026
7079
0.130
Why?
Antineoplastic Agents
2
2019
2218
0.120
Why?
Aspirin
1
2020
404
0.120
Why?
Pilot Projects
1
2022
1878
0.120
Why?
Piperazines
1
2019
367
0.120
Why?
Economics, Pharmaceutical
1
2016
10
0.120
Why?
Medication Errors
1
2017
86
0.120
Why?
Models, Statistical
1
2020
667
0.120
Why?
Child, Preschool
4
2026
11888
0.120
Why?
Feasibility Studies
1
2020
1125
0.120
Why?
Antirheumatic Agents
1
2019
309
0.120
Why?
Child
7
2026
22638
0.120
Why?
Hematologic Neoplasms
1
2018
169
0.120
Why?
Sepsis
1
2022
668
0.120
Why?
Spirometry
1
2016
234
0.110
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2018
299
0.110
Why?
Quality of Life
3
2024
3187
0.110
Why?
Information Dissemination
1
2017
224
0.110
Why?
Indoles
1
2019
509
0.110
Why?
Alzheimer Disease
1
2021
640
0.110
Why?
Primary Health Care
1
2025
1768
0.110
Why?
Intellectual Property
3
2019
7
0.100
Why?
Venous Thromboembolism
1
2019
330
0.100
Why?
Telemedicine
1
2024
956
0.100
Why?
Eosinophils
1
2016
319
0.100
Why?
Canada
1
2015
430
0.100
Why?
Antibodies, Anti-Idiotypic
1
2014
50
0.100
Why?
Chronic Disease
3
2026
1824
0.100
Why?
Observational Studies as Topic
1
2014
133
0.100
Why?
Pragmatic Clinical Trials as Topic
1
2014
135
0.100
Why?
Anticoagulants
1
2019
743
0.100
Why?
Sex Factors
2
2017
2101
0.100
Why?
JC Virus
1
2013
22
0.100
Why?
Delivery of Health Care
1
2019
942
0.090
Why?
Fasting
1
2014
280
0.090
Why?
Socioeconomic Factors
1
2017
1323
0.090
Why?
Ergocalciferols
1
2012
15
0.090
Why?
Diabetes Complications
1
2014
219
0.090
Why?
Analysis of Variance
1
2014
1293
0.090
Why?
Age Factors
2
2017
3321
0.090
Why?
Comorbidity
2
2014
1652
0.090
Why?
Income
1
2012
205
0.080
Why?
International Classification of Diseases
2
2022
142
0.080
Why?
Receptors, Antigen, T-Cell
3
2019
676
0.080
Why?
Unemployment
1
2010
43
0.080
Why?
Prescription Drugs
1
2012
110
0.080
Why?
Diabetic Nephropathies
1
2014
320
0.080
Why?
Diagnostic Tests, Routine
1
2011
108
0.080
Why?
Vitamin D Deficiency
1
2012
188
0.080
Why?
Arthritis, Rheumatoid
1
2019
1184
0.070
Why?
Databases, Factual
1
2015
1481
0.070
Why?
Dose-Response Relationship, Drug
3
2020
2018
0.070
Why?
Infant
3
2026
10093
0.070
Why?
Anti-Bacterial Agents
1
2019
1935
0.070
Why?
Vitamin D
1
2012
402
0.070
Why?
Immunosuppressive Agents
1
2013
824
0.070
Why?
Depressive Disorder
1
2010
359
0.070
Why?
Epilepsy
1
2012
397
0.070
Why?
Uncertainty
2
2019
145
0.060
Why?
Multiple Sclerosis
1
2011
434
0.060
Why?
Cohort Studies
4
2019
6045
0.060
Why?
Cost Savings
1
2024
85
0.050
Why?
Demography
1
2024
274
0.050
Why?
C-Peptide
1
2025
191
0.050
Why?
Hemorrhage
2
2020
824
0.050
Why?
Neurologists
1
2024
22
0.050
Why?
Consensus
1
2025
465
0.050
Why?
Needs Assessment
1
2026
403
0.050
Why?
Sexual Partners
1
2024
195
0.050
Why?
Recurrence
2
2018
1125
0.050
Why?
Home Care Services
1
2026
290
0.050
Why?
Glatiramer Acetate
2
2013
11
0.050
Why?
Stress, Psychological
1
2010
1169
0.040
Why?
Pregnancy
2
2024
7217
0.040
Why?
Massachusetts
1
2022
178
0.040
Why?
Intensive Care Units, Neonatal
1
2024
295
0.040
Why?
Risk Factors
3
2024
10840
0.040
Why?
Menopause
1
2023
327
0.040
Why?
Clinical Trials, Phase II as Topic
1
2019
74
0.040
Why?
Off-Label Use
1
2019
50
0.040
Why?
Receptors, Interleukin-6
1
2019
49
0.040
Why?
Vancomycin
1
2019
96
0.030
Why?
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
2019
91
0.030
Why?
Antimetabolites, Antineoplastic
1
2018
108
0.030
Why?
Population Surveillance
1
2021
477
0.030
Why?
Algorithms
1
2026
1843
0.030
Why?
Drug Approval
1
2018
93
0.030
Why?
Thrombocytopenia
1
2019
205
0.030
Why?
Venous Thrombosis
1
2019
195
0.030
Why?
Pulmonary Embolism
1
2019
245
0.030
Why?
Asia
1
2016
69
0.030
Why?
Peptides
2
2013
991
0.030
Why?
Congresses as Topic
1
2017
226
0.030
Why?
Medicine
1
2017
126
0.030
Why?
Policy Making
1
2016
83
0.030
Why?
Administration, Inhalation
1
2017
567
0.030
Why?
Survival Analysis
1
2019
1372
0.030
Why?
Biological Products
1
2019
257
0.030
Why?
HIV Infections
2
2024
3210
0.030
Why?
Hospitals
1
2019
730
0.030
Why?
Monte Carlo Method
1
2014
150
0.030
Why?
Cystatin C
1
2014
65
0.030
Why?
Probability
1
2014
308
0.020
Why?
Adrenal Cortex Hormones
1
2016
483
0.020
Why?
Length of Stay
1
2019
1342
0.020
Why?
Propylene Glycols
1
2013
27
0.020
Why?
Fingolimod Hydrochloride
1
2013
35
0.020
Why?
Sphingosine
1
2013
46
0.020
Why?
Infant, Newborn
1
2024
6449
0.020
Why?
Vascular Calcification
1
2014
109
0.020
Why?
Intensive Care Units
1
2019
923
0.020
Why?
Linear Models
1
2014
847
0.020
Why?
Critical Illness
1
2019
905
0.020
Why?
Drug Evaluation
1
2012
78
0.020
Why?
Efficiency
1
2012
102
0.020
Why?
Health Services
1
2012
112
0.020
Why?
Mitoxantrone
1
2011
14
0.020
Why?
Hematologic Tests
1
2011
22
0.020
Why?
Interferon-beta
1
2011
90
0.020
Why?
Employment
1
2012
180
0.020
Why?
Clinical Laboratory Techniques
1
2011
96
0.020
Why?
Respiratory Function Tests
1
2011
543
0.020
Why?
Pulmonary Disease, Chronic Obstructive
1
2016
926
0.020
Why?
Health Surveys
1
2010
511
0.020
Why?
Electrocardiography
1
2011
666
0.020
Why?
Interviews as Topic
1
2010
926
0.020
Why?
Antibodies, Monoclonal
1
2011
1511
0.010
Why?
Electronic Health Records
1
2012
1208
0.010
Why?
Magnetic Resonance Imaging
1
2011
3917
0.010
Why?
McQueen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)